4SC-203

4SC-203 is a small molecule multikinase inhibitor developed for oncology indications. It selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), including FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). By targeting these kinases, which are often upregulated in certain cancers such as acute myeloid leukemia (AML), the drug aims to inhibit angiogenesis and tumor cell proliferation. Preclinical studies demonstrated strong selectivity against FLT3/FLT3 mutants and VEGFRs. The compound was administered intravenously in clinical trials and showed a favorable safety profile in healthy volunteers during Phase I studies. Development was discontinued after early-phase clinical evaluation[1][2][3][4][5][6].

Other names

UNII-RFG3GJ6251UNII-RFG-3GJ6251UNII-RFG 3GJ62514sc 203Urea N-(2-methoxy-5-methylphenyl)-N'-(6-((6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-4-quinazolinyl)amino)-2-benzothiazolyl)4SC 203 [WHO-DD]